The transition from traditional trial-and-error chemical assays to high-precision computational forecasting has effectively rewritten the blueprint for modern therapeutic development across the global pharmaceutical industry. This evolution is particularly evident in the fight against Idiopathic
Ivan Kairatov is a distinguished biopharma expert with a deep background in research and development, focusing on the intersection of technology and patient-centric innovation. In this discussion, we explore the implications of the U.S. FDA’s recent acceptance of Gilead’s supplemental New Drug
The traditional reliance on non-selective systemic chemotherapy for treating advanced gynecological malignancies is rapidly fading as clinicians embrace the precision of antibody–drug conjugates. For decades, the standard approach to ovarian, cervical, and endometrial cancers involved cytotoxic
The historical paradigm where Western laboratories exclusively dictated the rhythm of pharmaceutical progress is rapidly disintegrating as China establishes itself as a primary source of high-value drug candidates. For many decades, the global healthcare sector followed a remarkably predictable
The emergence of chimeric antigen receptor T-cell therapy has revolutionized the oncological landscape by providing a potent "living drug" that can hunt and destroy malignant cells, yet nearly half of all patients still experience clinical relapses that threaten the long-term viability of this
The journey of a life-saving injectable molecule often begins with a deceptive sense of simplicity on a laboratory bench, only to face an unforgiving reality when moved toward large-scale clinical manufacturing. While the ambition to reach in-human trials quickly is a common driver for drug owners,
